Motorsport Games Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Motorsport Games Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2022 | $741.0K | Mar 30, 2022 |
| FY2022 | Dec 31, 2021 | $741.0K | Mar 24, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.30M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $8.69M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $6.91M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $15.08M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $19.05M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $11.85M | Mar 24, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.20M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $5.46M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.29M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $5.36M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.55M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $12.45M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.96M | Mar 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.93M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($2.75M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($14.32M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($35.99M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $288.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.76M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($3.56M) | Mar 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.25M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($1.75M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($16.37M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($35.03M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($34.53M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.1K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($5.18M) | Mar 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.38M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $7.24M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.62M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.65M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $4.78M | Mar 24, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.07M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($2.84M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($13.65M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($19.52M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($20.94M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.05M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($4.42M) | Mar 24, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.1K | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $25.0K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $31.7K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $292.4K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $754.3K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $136.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $108.3K | Mar 24, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.97M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $6.27M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $9.76M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $18.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $50.70M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $17.39M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $12.78M | Mar 24, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.39M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $5.04M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $7.67M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $16.99M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.72M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $15.77M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $9.17M | Mar 24, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.78M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $496.3K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.04M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.53M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $36.72M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.03M) | Mar 30, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $4.87M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $137.7K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $137.7K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $712.7K | Mar 24, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.86M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($91.79M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($89.04M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($73.98M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($37.99M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($4.83M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.99M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $859.3K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.68M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $979.3K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $17.82M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.99M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.96M | Mar 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 30 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (29) | Mar 24, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 30 | Apr 1, 2024 |